Thompson Siegel & Walmsley LLC Coherus Bio Sciences, Inc. Transaction History

Thompson Siegel & Walmsley LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	BUY	$7.17 - $13.87 $6,123 - $11,844	854 Added 9.27%	10,070 $97,000
Q2 2022 Jul 22, 2022	SELL	$5.86 - $13.23 $4.08 Million - $9.21 Million	-696,440 Reduced 98.69%	9,216 $67,000
Q1 2022 Apr 26, 2022	BUY	$10.92 - $16.41 $1.61 Million - $2.42 Million	147,193 Added 26.36%	705,656 $9.11 Million
Q4 2021 Feb 09, 2022	SELL	$15.81 - $18.99 $694,185 - $833,812	-43,908 Reduced 7.29%	558,463 $8.91 Million
Q3 2021 Nov 05, 2021	SELL	$12.68 - $17.79 $2.63 Million - $3.68 Million	-207,042 Reduced 25.58%	602,371 $9.68 Million
Q2 2021 Aug 09, 2021	BUY	$12.95 - $15.41 $1.88 Million - $2.23 Million	144,850 Added 21.8%	809,413 $11.2 Million
Q1 2021 May 07, 2021	BUY	$14.42 - $21.39 $2.2 Million - $3.27 Million	152,710 Added 29.83%	664,563 $9.71 Million
Q4 2020 Feb 08, 2021	BUY	$16.56 - $18.94 $2.27 Million - $2.6 Million	137,168 Added 36.61%	511,853 $8.9 Million
Q3 2020 Nov 12, 2020	SELL	$17.41 - $19.89 $1.02 Million - $1.16 Million	-58,532 Reduced 13.51%	374,685 $6.87 Million
Q2 2020 Aug 11, 2020	BUY	$14.43 - $19.16 $6.25 Million - $8.3 Million	433,217 New	433,217 $7.74 Million

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Thompson Siegel & Walmsley LLC, based on Form 13F filings with the SEC.

Stay updated on Thompson Siegel & Walmsley LLC with notifications on news.